Trial Profile
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Moderate Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions
- Sponsors Idorsia Pharmaceuticals
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 20 Sep 2019 Status changed from recruiting to completed.
- 18 Sep 2019 Planned End Date changed from 31 Jul 2019 to 30 Sep 2019.